Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab

for COVID 2 Columbus Working Group

Research output: Contribution to journalArticlepeer-review

Abstract

A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.

Original languageEnglish
Pages (from-to)767-771
Number of pages5
JournalInfection
Volume48
Issue number5
DOIs
Publication statusPublished - Oct 1 2020

Keywords

  • Baricitinib
  • COVID-19
  • Immunotherapy
  • Sarilumab
  • SARS-CoV-2

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab'. Together they form a unique fingerprint.

Cite this